AirNOvent

AirNOvent* is a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. Inhaled nitric oxide is a pulmonary vasodilator, which is approved in the United States for use as part of a regimen in the treatment of hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN). The currently available product, INOMAX®, is used in neonatal intensive care units and its delivery system administers nitric oxide from pressurized cylinders in conjunction with ventilator systems.

Product progress

In early 2019, Circassia’s partner, AIT Therapeutics, successfully completed a pre-submission meeting with the US Food and Drug Administration (FDA). AIT anticipates submitting a Premarket Approval application in Q2 2019 for AirNOvent for use in the treatment of hypoxic respiratory failure associated with PPHN.

*AirNOvent is not an approved name for the product and may not be the final name submitted for approval